ライフサイエンスコーパス: tetanus

1 immobilizing whole-body muscle contraction (tetanus).

2 rogress in eliminating maternal and neonatal tetanus.

3 nknown number of mothers die every year from tetanus.

4 eases as anthrax, botulism, gas gangrene and tetanus.

5 ted head wound can be confused with cephalic tetanus.

6 asant odor and a possible heightened risk of tetanus.

7 or vaccination responses against measles and tetanus.

8 31.97 [IQR, 18.58-61.80] mg/L; P = .02), and tetanus (0.08 [IQR, 0.03-0.39] IU/mL vs 0.24 [IQR, 0.08-

9 d, 1 year after the program using diphtheria-tetanus-5-component acellular pertussis-inactivated poli

10 Contrariwise, tetanus AB (non-brain-binding) were present in serum and

11 valent pneumococcal and combined diphtheria, tetanus, acellular pertussis, inactivated polio, hepatit

12 that delay in vaccines containing diphtheria-tetanus-acellular pertussis (DTaP) is associated with re

13 who received at least 3 doses of diphtheria-tetanus-acellular pertussis vaccine by the end of 15 mon

14 t cohorts that received different diphtheria-tetanus-acellular pertussis vaccines (DTaP) during child

15 : combination diphtheria vaccine (diphtheria-tetanus-acellular pertussis-inactivated poliovirus/Haemo

16 onsistent limb group received the diphtheria-tetanus-acellular pertussis-inactived polio-Haemophilus

17 ck, eel discharges cause brief, immobilizing tetanus, allowing eels to swallow small prey almost imme

18 ell numbers were not affected, nor were anti-tetanus and anti-measles immunoglobulin G levels.

19 CNTs) responsible for the paralytic diseases tetanus and botulism, respectively.

20 ts aged >/=65 years who received the Tdap or tetanus and diphtheria (Td) vaccine during 1 January 200

21 clinically protective level of 0.1 IU/mL for tetanus and diphtheria antibodies at age 7 years.

22 ly 97% of the population was seropositive to tetanus and diphtheria as defined by a protective serum

23 the population will remain protected against tetanus and diphtheria for >/=30 years without requiring

24 t the current adult vaccination schedule for tetanus and diphtheria should be revisited.

25 for Disease Control and Prevention recommend tetanus and diphtheria toxoids and acellular pertussis (

26 papillomavirus, meningococcal conjugate, and tetanus and diphtheria toxoids and acellular pertussis v

27 tetanus toxoids and acellular pertussis, and tetanus and diphtheria toxoids and acellular pertussis v

28 adult immunization schedules recommend that tetanus and diphtheria vaccination be performed every 10

29 ibody titers were 3.6 and 0.35 IU/mL against tetanus and diphtheria, respectively.

30 d stocking seasonal influenza; pneumococcal; tetanus and diphtheria; and tetanus, diphtheria, and ace

31 chieved protective thresholds; antibodies to tetanus and Hib were higher.

32 , children receive five doses of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine before 7

33 -year-old age group despite high diphtheria, tetanus, and acellular pertussis vaccine (DTaP) coverage

34 , and parenteral vaccines against pertussis, tetanus, and measles in an observational study that moni

35 e platform for integrating measles, neonatal tetanus, and other vaccine-preventable disease surveilla

36 to examine trends in coverage of diphtheria, tetanus, and pertussis (DTP) vaccination across 190 coun

37 ird dose of a vaccine containing diphtheria, tetanus, and pertussis antigens (DTP3) was >/=90% in 14

38 o had received the third dose of diphtheria, tetanus, and pertussis vaccine were randomly assigned to

39 mary course only (three doses of diphtheria, tetanus, and pertussis vaccines [DTP3] commencing in 198

40 estimates, and country-specific diphtheria, tetanus, and pertussus vaccination coverage rates to est

41 entavalent vaccine (which covers diphtheria, tetanus, and whole-cell pertussis; hepatitis B; and Haem

42 , especially at age 7 years, except that the tetanus antibody level following PFOS exposure was not s

43 All antibodies bound to tetanus antigen with high affinity, ranging from 0.23 to

44 1 million cases of tetanus are estimated to occur worldwide each year, with

45 pothesis that improved community immunity to tetanus as a result of the PsA-TT campaigns may be havin

46 opment of therapeutics for the prevention of tetanus by targeting this protein-protein interaction.

47 Tetanus can present with unusual clinical forms; therefo

48 Few associations were observed for anti-tetanus concentrations.

49 st that relatively recent receipt of a prior tetanus-containing vaccination does not increase risk af

50 birth outcomes related to timing since prior tetanus-containing vaccination.

51 received Tdap in pregnancy following a prior tetanus-containing vaccine less than 2 years before, 2 t

52 nated with Tdap in pregnancy and had a prior tetanus-containing vaccine more than 5 years before serv

53 2+) concentrations in the case of twitch and tetanus, corresponding to different applied currents.

54 responses to respiratory syncytial virus and tetanus could not be detected above the background level

55 Antibody responses to tetanus declined with an estimated half-life of 14 years

56 Successful treatment of tetanus depends on prompt diagnosis of clinical tetanus,

57 interval compared to the prior 12 months for tetanus diphtheria combination, 23-valent pneumococcal p

58 The effect a maternal tetanus, diphtheria, acellular pertussis (Tdap) vaccine

59 onths after delivery in women immunized with tetanus, diphtheria, and acellular pertussis (Tdap) afte

60 Simultaneously, uptake of both tetanus, diphtheria, and acellular pertussis (Tdap) and

61 Immunization Practices (ACIP) recommends the tetanus, diphtheria, and acellular pertussis (Tdap) vacc

62 Women are recommended to receive tetanus, diphtheria, and acellular pertussis (Tdap) vacc

63 All US women are recommended to receive a tetanus, diphtheria, and acellular pertussis (Tdap) vacc

64 several countries have recommended universal tetanus, diphtheria, and acellular pertussis immunisatio

65 Tetanus, diphtheria, and acellular pertussis vaccination

66 ng decennial tetanus-diphtheria booster with tetanus, diphtheria, and acellular pertussis vaccine for

67 a; pneumococcal; tetanus and diphtheria; and tetanus, diphtheria, and acellular pertussis vaccines.

68 Thirty infants of Tdap (tetanus, diphtheria, and acellular pertussis)-vaccinated

69 uch as exposure to pyriproxyfen or vaccines (tetanus, diphtheria, and acellular pertussis, measles an

70 rtussis vaccination (eg, replacing decennial tetanus-diphtheria booster with tetanus, diphtheria, and

71 ter (GW 13-25) vs third-trimester (>/=GW 26) tetanus-diphtheria-acellular pertussis (Tdap) immunizati

72 sis mortality in high-income countries using tetanus-diphtheria-acellular pertussis (Tdap) vaccines i

73 estimated the vaccine effectiveness (VE) of tetanus-diphtheria-acellular pertussis vaccine (Tdap) fo

74 Published data on the safety of tetanus-diphtheria-acellular pertussis vaccine (Tdap) in

75 ne site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve

76 anuary 2012, the scheduled administration of tetanus/diphtheria/acellular pertussis and meningococcal

77 the characteristic paralyses of botulism and tetanus during bacterial infection.

78 No pre-/post-tetanus effects were found in either subject group for t

79 No pre-/post-tetanus effects were found in SZ.

80 The Maternal and Neonatal Tetanus Elimination Initiative, launched by WHO and its

81 the NMDA receptor-mediated component of the tetanus-evoked responses.

82 Neonatal cases of tetanus fell by 25% in countries that completed PsA-TT c

83 induce up to 1.7-fold increase in twitch and tetanus force amplitude.

84 n), measles (from 0.63 to 0.13 million), and tetanus (from 0.27 to 0.06 million).

85 ells and were randomly assigned to receive a tetanus helper peptide or a mixture of six melanoma-asso

86 in (FHA), fimbriae 2 + 3 (FIMs), diphtheria, tetanus, Hib, MCC and PCV13 serotypes were compared to r

87 r vaccination with PsA-TT effectively boosts tetanus immunity in a population with heterogeneous base

88 in a population with heterogeneous baseline tetanus immunity is not known.

89 t vaccines because of their ability to boost tetanus immunity.

90 asters strike in developing countries, where tetanus immunization coverage is often low or nonexisten

91 We report a case of generalised tetanus in a 22-year-old woman that arose despite the pr

92 Ca(2+) release in response to a presynaptic tetanus in an SN that induces PTP can confer transient p

93 aving an impact on the incidence of neonatal tetanus in sub-Saharan Africa.

94 ed Ca(2+) release event by either a synaptic tetanus in the presence of 3-((R)-2-carboxypiperazine-4-

95 Vaccination with 12MP plus tetanus induced CD8(+) T-cell responses in 78% of patien

96 the prey's location and eliciting the full, tetanus-inducing volley.

97 The emergency response to clusters of tetanus infections in developing countries after a natur

98 The success of tetanus, influenza, and pertussis immunisation during pr

99 Tetanus is a life-threatening but preventable disease ca

100 Tetanus is almost completely preventable by active immun

101 Tetanus is an expected complication when disasters strik

102 Maternal and neonatal tetanus is still a substantial but preventable cause of

103 nd, antenatal pertussis immunization using a tetanus/low-dose diphtheria/5-component acellular-pertus

104 on programs to prevent maternal and neonatal tetanus, maternal immunization has been well received in

105 However, only tetanus, measles, AIDS, and malaria (in Africa) decrease

106 Tetanus neurotoxin (TeNT) and botulinum neurotoxin (BoNT

107 Botulinum neurotoxins (BoNTs) and tetanus neurotoxin (TeNT) are the most toxic proteins fo

108 Tetanus neurotoxin (TeNT) causes neuroparalytic disease

109 Tetanus neurotoxin (TeNT) is among the most poisonous su

110 not v-SNAREs (synaptobrevins/VAMP1/2/3 using tetanus neurotoxin (TeNT), also in TI-VAMP/VAMP7 knock-o

111 and include botulinum neurotoxins (BoNT) and tetanus neurotoxin (TeNT).

112 Botulinum neurotoxins (BoNTs) and tetanus neurotoxin are the causative agents of the paral

113 t RSK2 and PLD1 positively control fusion of tetanus neurotoxin insensitive vesicle-associated membra

114 ed vectors were co-transported with both the tetanus neurotoxin-binding fragment and the membrane pro

115 Tetanus neurotoxin-insensitive vesicular-associated memb

116 The same synaptic tetanus often evoked NMDA spike-mediated [Ca(2+)](i) inc

117 en and 37 infants of women vaccinated with a tetanus-only vaccine received a fourth aP-containing vac

118 alently attached to protein carriers such as tetanus or diphtheria toxoids.

119 % of patients and CD4(+) T-cell responses to tetanus peptide in 93% of patients.

120 proved coverage in three doses of diphtheria tetanus pertussis containing vaccine between 2013 and 20

121 ly new strategy, and is currently limited to tetanus, pertussis, and influenza vaccines.

122 ve OPV with pentavalent vaccine (diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and h

123 nt vaccines: polio, pentavalent (diphtheria, tetanus, pertussis, hepatitis B virus, and Haemophilus i

124 Plasma IgG levels specific for diphtheria, tetanus, pertussis, measles, rubella, and Haemophilus in

125 was inactivated vaccine against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae ty

126 enting for the second dose of the diphtheria-tetanus-pertussis vaccination (given at 8-10 weeks of ag

127 d coverage with the third dose of diphtheria-tetanus-pertussis vaccine (DTP3) to district-reported co

128 he routine immunization schedule: diphtheria-tetanus-pertussis vaccine dose 1 (DTP1), DTP2, DTP3, and

129 f Immunisation (eg, BCG, measles, diphtheria-tetanus-pertussis, and three doses of polio) doubled ove

130 of annual national third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3) and third do

131 ual improvement in third dose of diphtheria- tetanus-pertussis-containing vaccine (DTP3) coverage in

132 utable to the vaccination against diphtheria-tetanus-pertussis-poliomyelitis (OR = 1.5) and was not s

133 cillus Calmette-Guerin, diphtheria-pertussis-tetanus, polio, and maternal tetanus vaccinations.

134 hort-term homosynaptic plasticity induced by tetanus [post-tetanic potentiation (PTP)] or low-frequen

135 calating doses (0.5, 2.5, 10 mg) of PADRE or Tetanus pp65(495-503) vaccines with (30 adults) or witho

136 finding that LTP induced by prolonged theta tetanus (PTT-LTP) depends on Cav1.2 and its regulation b

137 accine except for Tdap (adolescent and adult tetanus, reduced diphtheria, acellular pertussis) vaccin

138 Maternal vaccination with tetanus, reduced-dose diphtheria, and acellular pertussi

139 gents of the paralytic diseases botulism and tetanus, respectively.

140 ynthetic Pan DR epitope [PADRE] or a natural Tetanus sequence) were clinically evaluated for safety a

141 PsA-TT generated robust tetanus serologic responses in 1- to 29-year-olds, simil

142 in Africa assessed whether PsA-TT generated tetanus serologic responses when tested in African popul

143 We observed intact or enhanced tetanus-specific and total IgG ASC frequency, serum IgG,

144 G Ab-secreting cell (ASC) frequency, HCV and tetanus-specific ASC frequency, BCR- and CD40L-dependent

145 inding, whereas positive-control staining of tetanus-specific CD4 T cells was routinely successful.

146 lthough frequencies were lower compared with tetanus-specific cells.

147 toxic CD8 T-cell epitope from CMV pp65 and a tetanus T-helper epitope.

148 In addition, slow muscle twitch, tetanus tension, and susceptibility to injury were all s

149 ocampal pyramidal neurons that occurs during tetanus, thus opposing the induction of synaptic plastic

150 e intracellular Ca(2+) handling and increase tetanus-to-twitch ratio.

151 Botulinum neurotoxins (BoNTs) and tetanus toxin (TeNT) are the most potent toxins for huma

152 n by different neuronal subtypes, we express tetanus toxin (TeNT) in individual reticulospinal or CoP

153 Six rats received injections of tetanus toxin (TeTX) in the ventral hippocampus that res

154 nditional expression of the light chain from tetanus toxin (tox) in raphe neurons expressing serotone

155 ptic transmission of select PVT neurons with tetanus toxin activated via retrograde trans-synaptic tr

156 Cleavage of VAMP2 and VAMP3 with tetanus toxin blocked cAMP-stimulated renin release from

157 Furthermore, B-cell responses to tetanus toxin but not influenza hemagglutinin in the ART

158 Intramuscular injections of Tetanus Toxin C-fragment (TTc) labeled with Alexa 790 fl

159 We find that the axons of individual tetanus toxin expressing reticulospinal neurons have few

160 egion- and cell-type-selective expression of tetanus toxin light chain (TeLC) and compared the functi

161 Silencing BPNs with tetanus toxin light chain (TeNT) increases bilateral mas

162 or targeted astrocyte-specific expression of tetanus toxin light chain (to interfere with vesicular r

163 f serotonergic and raphe neurons in mice for tetanus toxin light chain expression, which prevented ve

164 an adenoviral vector to specifically express tetanus toxin light chain in astrocytes) reduced the HVR

165 using Cre-inducible viral expression of the tetanus toxin light chain in male and female PV-Cre mice

166 culum by injecting a viral vector expressing tetanus toxin light chain in male mice.

167 By expressing either tetanus toxin light chain or diphtheria toxin in gal4-de

168 nergic neurons, we inactivated them with the tetanus toxin light chain, a genetically encoded inhibit

169 , unc-1(dn) has effects opposite to those of tetanus toxin light chain, separating the roles of ADL e

170 dorant stimuli, optogenetics, and transgenic tetanus toxin neurotransmission block show that elevated

171 Expression of tetanus toxin to cleave VAMP2 in VAMP8 knock-out (-/-) a

172 ely, blocking glutamate release by targeting tetanus toxin to individual synapses increases alpha7-nA

173 g the pE88 plasmid, which encodes the lethal tetanus toxin, and thus a potential target for drug desi

174 p53, HER2-ICD, HER2-ECD, and CEA, but not to tetanus toxin, relative to controls and surgically resec

175 /C entered cells differently than the HCR of tetanus toxin, which also utilizes dual gangliosides as

176 ced TNF exocytosis in BMMCs was dependent on tetanus toxin-insensitive vesicle-associated membrane pr

177 We now find that the v-SNARE tetanus toxin-insensitive vesicle-associated membrane pr

178 by unilateral intrahippocampal injection of tetanus toxin.

179 In stark contrast, myelination along tetanus-toxin-expressing CoPA neuron axons is entirely n

180 At 12 wk, tetanus toxoid (0.5 mL intramuscular) and Pneumovax II v

181 l polysaccharide of serotype 1 conjugated to tetanus toxoid (Pnc1-TT) as a model vaccine.

182 d to the minimal domain of the C fragment of tetanus toxoid (referred to herein as Tem1-TT vaccine).

183 Specific antibodies binding to tetanus toxoid (total IgG) and pneumococcal capsular pol

184 eningococcal conjugate vaccine, PsA-TT, uses tetanus toxoid (TT) as a carrier protein (PsA-TT).

185 gG and B-cell receptor repertoires following tetanus toxoid (TT) booster vaccination.

186 mmunization of mice with an optimized heroin-tetanus toxoid (TT) conjugate formulated with adjuvants

187 We assessed the impact of PsA-TT on tetanus toxoid (TT) immunity by quantifying age- and sex

188 nt influenza seasonal subunit vaccine and to tetanus toxoid (TT) in mouse.

189 (+) T cells that proliferated in response to tetanus toxoid (TT) presented by autologous CD B cells.

190 oconjugate made by conjugating this with the tetanus toxoid (TT) protein have been characterized and

191 polysaccharides, and very different from the tetanus toxoid (TT) protein used for the conjugation.

192 osaccharide units (9Glc-NH(2)) conjugated to tetanus toxoid (TT) to induce antibodies in rabbits.

193 MV infection or were recently immunized with tetanus toxoid (TT) were included as controls.

194 CFSE-labeled PBMCs were stimulated with CMV, tetanus toxoid (TT), and C albicans antigens and subsequ

195 entous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were mea

196 y normal human mononuclear cells, induced by tetanus toxoid (TT), human thyroglobulin (TG), Escherich

197 encapsulation of two antigens, ovalbumin and tetanus toxoid (TT), in PLGA microspheres was adjusted b

198 D4(+) T cells via a carrier protein, such as tetanus toxoid (TT), resulting in the induction of PS-sp

199 C meningococcal polysaccharides, as well as tetanus toxoid (TT), was used to investigate the BCR rep

200 HIV-1 envelope glycoprotein (CN54gp140) and tetanus toxoid (TT).

201 olysaccharide (GBSIII) to ovalbumin (OVA) or tetanus toxoid (TT).

202 ontrol mice at the time of immunization with tetanus toxoid adsorbed to aluminum hydroxide (TT/Alum).

203 ast Sweden cohort, were stimulated with Ags (tetanus toxoid and beta-lactoglobulin) and diabetes-rela

204 donors to retrieve human antibodies against tetanus toxoid and influenza hemagglutinin (HA) from H1N

205 Hapten 1 was conjugated to tetanus toxoid and mixed with liposomes containing monop

206 XmAb5871 suppressed humoral immunity against tetanus toxoid and reduced serum IgM, IgG, and IgE level

207 investigated in in vitro cocultures by using tetanus toxoid and Salmonella species as antigen models.

208 Anti-tetanus toxoid antibody IgG geometric mean concentration

209 affect preexisting antipneumococcal or anti-tetanus toxoid antibody levels.

210 characterization of memory B cells by using tetanus toxoid as a model antigen.

211 n of the group A polysaccharide and used its tetanus toxoid as the carrier protein to produce the now

212 ningococcal conjugate vaccine that used SIIL tetanus toxoid as the carrier protein.

213 , B cells and moDCs were pulsed with IgE-NIP-tetanus toxoid complexes and cocultured with autologous

214 s incorporated into the original beta-mannan tetanus toxoid conjugate providing a tricomponent conjug

215 cine against Candida albicans, a beta-mannan tetanus toxoid conjugate showed poor immunogenicity in m

216 and capsular group C Neisseria meningitidis tetanus toxoid conjugate vaccine (Hib-MenC-TT), administ

217 A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) wa

218 V is a single-dose typhoid Vi polysaccharide-tetanus toxoid conjugate vaccine for persons >/=6 months

219 wledge gap, we assessed the efficacy of a Vi-tetanus toxoid conjugate vaccine using an established hu

220 ia meningitidis group A (NmA) polysaccharide-tetanus toxoid conjugate vaccine, PsA-TT (MenAfriVac), d

221 A monovalent MenA polysaccharide-tetanus toxoid conjugate was therefore developed.

222 C-PS, a TI Ag, or a conjugate of MenC-PS and tetanus toxoid elicited an augmented PS-specific IgG res

223 Measles and tetanus toxoid IgGs were measured quantitatively by usin

224 ells, peripheral plasmablasts isolated after tetanus toxoid immunization and memory B cells isolated

225 ent conjugate of (poly)glycerolphosphate and tetanus toxoid in alum plus CpG-oligodeoxynucleotides pr

226 Surprisingly, in the ISCOMs, the tetanus toxoid is located just below the membrane inside

227 ific for epitopes of HCMV phosphoprotein-65, tetanus toxoid precursor, EBV nuclear Ag 2, or HIV gag p

228 iour and unlike the previously characterised tetanus toxoid protein (slightly extended and hydrodynam

229 th a then-new meningococcal A polysaccharide-tetanus toxoid protein conjugate vaccine (PsA-TT, or Men

230 Conjugation with tetanus toxoid protein however greatly increased the mol

231 articular, MUC1 glycopeptide conjugates with Tetanus toxoid proved to be efficient vaccines inducing

232 erythrocytes, vaccinia virus, rotavirus, or tetanus toxoid provides evidence for reactivation of ane

233 ll responses against autoantigen or repeated tetanus toxoid stimulations require both Kv1.3 and KCa3.

234 ls with CpG ODN also enabled presentation of tetanus toxoid to CD8(+) T cells, resulting in CD8(+) T

235 aluminum phosphate, a commercially available tetanus toxoid vaccine adjuvanted with potassium alum, a

236 erated after immunizations with conventional tetanus toxoid vaccine, and (2) preventing pathological

237 ricomponent vaccine, but not the beta-mannan tetanus toxoid vaccine, showed activation of BMDCs.

238 ur cells in culture, while MUC1 glycopeptide-Tetanus toxoid vaccines elicited antibodies in mice whic

239 omain (ICD), HER2-ECD, p53, IGFBP2, CEA, and tetanus toxoid were examined.

240 Pf merozoite surface protein-1 (MSP-1), and tetanus toxoid were measured by indirect enzyme-linked i

241 ation with irradiated anti-RNP (but not anti-tetanus toxoid) CD4(+) cells induced remission of anti-R

242 from complete ISCOMs (i.e., with an antigen (tetanus toxoid) incorporated) can be modeled as a polydi

243 eonatal immunization with diphtheria toxoid, tetanus toxoid, and acellular pertussis vaccine has been

244 Currently inactivated influenza, tetanus toxoid, and acellular pertussis vaccines are rec

245 xoid cross-reactive material (CRM) 197 (DT), tetanus toxoid, and BSA, and combined with an adjuvant,

246 e prepared by coupling S. suis type 2 CPS to tetanus toxoid, and the immunological features of the po

247 < 0.01) but an increased immune response to tetanus toxoid, beta-lactoglobulin, and the autoantigens

248 fection or immunizations to influenza virus, tetanus toxoid, hepatitis B Ag, and human papillomavirus

249 tomegalovirus-pp65 (immunodominant protein), tetanus toxoid, measles, mumps, and rubella.

250 to recall Ags (purified protein derivative, Tetanus toxoid, or flu/EBV/CMV viral mix) in LN, despite

251 Maternal immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular

252 ia Department of Health recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular

253 fant contact, receive a single dose of Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular

254 In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular

255 les for certain vaccines (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid, and reduced a

256 plasmablast reactivity to a control antigen, tetanus toxoid, was minimal and similar in all groups.

257 ion of monocyte-derived dendritic cells, and tetanus toxoid-induced PBMC proliferation were assessed

258 Testing the distribution of tetanus toxoid-specific (TT(+)) mBCs revealed their pres

259 study the phenotype and frequency of D- and tetanus toxoid-specific B cells by culturing B cells in

260 Consistently, the avidity of tetanus toxoid-specific serum antibodies was substantial

261 ence in the increases in antibody binding to tetanus toxoid.

262 en because MSCs did not affect challenges to tetanus toxoid.

263 kin-13 (0.52, 0.34-0.82, 0.0005) response to tetanus toxoid.

264 immunisation coverage of pregnant women with tetanus toxoid.

265 red with other HIV antigens (such as p24) or tetanus toxoid.

266 djusted OR: 0.37; 95% CI 0.21-0.64) and with tetanus toxoidIgG3 levels equal or higher than the mean

267 safety study of a combination diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP),

268 cts received a single dose of diphtheria and tetanus toxoids and acellular pertussis vaccine 10 years

269 estational age and receipt of diphtheria and tetanus toxoids and acellular pertussis vaccine.

270 jugate, human papillomavirus, diphtheria and tetanus toxoids and acellular pertussis, and tetanus and

271 lescent/adult formulations of diphtheria and tetanus toxoids and acellular pertussis, meningococcal c

272 lescent/adult formulations of diphtheria and tetanus toxoids and acellular pertussis, pneumococcal co

273 %) had received >/=3 doses of diphtheria and tetanus toxoids and aP vaccine at the time of their firs

274 Undervaccination for the diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine.

275 has been included in the combined diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovir

276 anus depends on prompt diagnosis of clinical tetanus, treatment to ensure neutralization of circulati

277 muno-agent along with a pertussis-diphtheria-tetanus triple vaccine for autoimmune CP/CPPS developmen

278 maternal vaccine and to those conjugated to tetanus (TT) or the diphtheria toxin variant, CRM.

279 P) that developed shortly after a diphtheria tetanus vaccination is described, with a review of the l

280 ment of acute MMP shortly after a diphtheria tetanus vaccination may have been serendipitous, a resul

281 a pertussis and diphtheria component to the tetanus vaccination program in pregnant women in Vietnam

282 d vaccination, and in particular measles and tetanus vaccination, is associated with substantial redu

283 cluding local malaria transmission, neonatal tetanus vaccination, maternal age and education, and hou

284 erosions 2 days after receiving a diphtheria tetanus vaccination.

285 heria-pertussis-tetanus, polio, and maternal tetanus vaccinations.

286 h the third dose of the diphtheria-pertussis-tetanus vaccine (DPT3) and those who were immunized with

287 d second doses of diphtheria, pertussis, and tetanus vaccine (ie, 6 and 10 weeks of age, respectively

288 verage with 3rd dose of diphtheria-pertussis-tetanus vaccine in the 107 high-risk LGAs improved from

289 ed with a third dose of diphtheria-pertussis-tetanus vaccine, achieving 51% coverage during 2009 and

290 ing the CHDs instead of diphtheria-pertussis-tetanus vaccine, an additional 5000 children's lives cou

291 Cephalic tetanus was initially suspected but laboratory testing c

292 The incidence of tetanus was probably decreased by giving millions of dos

293 No subjective sensation of involuntary tetanus was reported, and aversive sensations were restr

294 ASs and of antibodies against diphtheria and tetanus were measured and were compared with data from t

295 ignalling pathways activated by the synaptic tetanus were not required.

296 Incidence data for neonatal tetanus were reviewed for countries with and without PsA

297 ccinations against diphtheria, pertussis and tetanus, which contained gelatin as a stabilizer.

298 ng term potentiation induced by a 5-Hz/180-s tetanus, which mimics the endogenous theta-rhythm and de

299 e who had only received 1 dose of Diphtheria Tetanus whole cell Pertussis (DTwP).

300 and death, as described following diphtheria-tetanus-whole cell pertussis (DTP) vaccination.